A phase I/II clinical trial of Carbon-ion therapy in 12 fractions over 3 weeks for patients with carcinoma of kidney

A phase I/II clinical trial of Carbon-ion therapy in 12 fractions over 3 weeks for patients with carcinoma of kidney - A Phase I/II trial of Carbon-ion therapy for Renal Cancer

Status

Unknown

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000008777

Enrollment

Registered

2012-09-01

Start date

2012-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal Cancer

Interventions

Radiotherapy (Carbon ion beam)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Pathologically confirmed renal cell carcinoma or renal tumor definitely diagnosed by the imaging as renal cell carcinoma. 2)Clear cell renal cell carcinoma, Chromophobe renal cell carcinoma, or Papillary renal cell carcinoma. 3)T1/T2N0M0 or T3 or more advanced tumor without tumor thrombus in the major vessels. 4)Performance status is 0 or 1

Exclusion criteria

Exclusion criteria: 1)Past history of radiotherapy to the corresponding site. 2)Prior administration of the molecular targeting drugs. 3)Difficult to reduce the dose to the bowels to lower than 60% of the prescribed dose. 4)Tumor exceeding 15cm in maximum diameter. 5)Atypical renal cancer such as Bellini duct carcinoma 6)Carcinome developed in dialyzed kidney 7)Active other malignancy

Design outcomes

Primary

Measure	Time frame
Acute radiation toxicity of normal tissue	—

Secondary

Measure	Time frame
Late radiation toxicity of normal tissue Local control rate Survival rate	—

Countries

Japan

Contacts

Public ContactTsuji Hiroshi

National Institute of Radiological Sciences Research Center for Charged particle therapy

h_tsuji@nirs.go.jp043-206-3360

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026